With LSN’s Redefining Early Stage Investments (RESI) conference coming up next Tuesday, I am delighted to announce the good news is RESI seems to have caught fire in the early stage global investor community, with investors making up half of the registered attendees.
The bad news is, when you add that to the fundraising CEOs, RESI Innovation Challenge participants, exhibitors and sponsors, we’ve reached capacity at our venue. We’re therefore unable to take any more registrations.
However, here’s the program guide; we hope that if you didn’t make it to RESI@JPM, you will be able to join us at one of our three events later this year in Houston (April 11th), Toronto (June 23rd), or Boston (September 13th). If you’d like to attend a future RESI event, plan early!
Life Science Nation’s mission of connecting scientist entrepreneurs with capital gave rise to the Redefining Early Stage Investments (RESI) conference nearly 3 years ago. As we approach our seventh RESI conference, during the highly anticipated JP Morgan week in San Francisco, we’re expecting a record of well over 300 investors representing over 200 different firms in attendance. Figure 1 shows a breakdown of investors by type who will be at RESI San Francisco on January 12, 2016. You can also view the firms represented here.
Venture capital is the most represented investor type, and this includes a growing number of non-traditional venture firms in today’s investment landscape. For instance, the relatively new emergence of the “micro VC” has more capital flowing into seed and series A stage companies. As shown here, several other investor classes looking for early-stage life science technologies that don’t fall under the venture capital umbrella also have a large presence at the RESI conference. This diversity of investors means that RESI Partnering can provide RESI’s great variety of attendees with the opportunity to make a connection with a financing partner that’s the right fit for their round.
Life Science Nation’s network of varied investor types will be showcased on an assortment of panels throughout the day. The 16 panels scheduled to take place at RESI San Francisco will cover the full range of companies in the life science space (biotech, medtech, diagnostic and health IT) and the different investor class’ tactical guidance for navigating the investment process of their respective niches and outlook on the future of each sector. The LSN research team’s unique perspective on the investment landscape has spurred a new panel that will be held for the first time at RESI San Francisco, Consumer Health “Investing in Innovative Products for Healthy Living,” and the return of two panels from former RESI events, Asia-Pacific Investors, “Forging Cross-Border Collaborations in Healthcare,” and Orphan & Rare Disease Investors, “Seeking Returns On Investing In Small Patient Populations”.
The fundraising process is typically a lengthy one, therefore multiple interactions with prospective investors and strategic partners are essential to a successful campaign. The RESI conference is an ongoing series that provides just that, allowing entrepreneurs to interface with a diverse field of investors, foster existing relationships and make new connections throughout the year, at multiple events. RESI San Francisco is just the first stop for 2016, with additional RESI conferences being held in Houston, Toronto and Boston, later in the year.
This ongoing chain of conferences coupled with the forward-looking investor mandate information used in our partnering platform really makes RESI stand out in terms of the ability to make meaningful connections. To see a demonstration of just how effective the partnering system can be at finding a match, please watch this video.
At LSN’s RESI San Francisco Conference next Tuesday, January 12th, the Corporate VC & Strategic Investment panel will focus on how major pharmaceutical companies evaluate and invest in early stage life science companies, both through corporate venture capital arms and internal investment units.
In this panel, corporate VC and major pharmaceutical investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and what to expect from an investment relationship with a large pharmaceutical company.
Moderated by Edward Hu, CFO & CIO of WuXi AppTec, the audience will hear from:
Carolyn E. Green, Executive Director, Strategic Investments, Worldwide R&D, Pfizer
If you’re a fundraising entrepreneur seeking strategic investments with a major pharmaceutical company, this panel is not one you want to miss. RESI San Francisco is already the largest RESI yet with over 700 attendees. This will be a great opportunity to expand your network in the life science space, so register now before it’s too late.
An investment fund offers business training programs for early stage ventures solving global challenges within several fields, including healthcare. The firm typically works with companies who have received less than $1 million in institutional funding and are looking to raise $500K or more in the next 12-18 months. In each program, 12innovative ventures are selected to participate, and among them, two will receive $50,000 investment each through a peer-selection process. The US-based programs are open to companies that are US-based, serving the US market, or with presence in the US.
Within healthcare, the firm is interested in entrepreneurs with solutions that will increase and/or improve access to both healthcare and treatment for low-wealth individuals. Examples may include healthcare IT solutions or innovative medtech and diagnostic tools. The program seeks companies that have developed some sort of traction, either revenue-based or meaningful customer feedback, user acquisition, successful pilots, or strategic partnerships.
The firm looks at experience, competency, and the overall dynamic of management teams. To participate in the business-training programs, the company must have at least one full time team member.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A private equity firm based in Shanghai, China, provides growth/expansion capital to companies with validated business models, with investments typically ranging from $10M-$100M. Investments are made into mature companies ready for an IPO within 12-18 months or earlier-stage companies with platform technologies or a broad portfolio of assets, especially therapeutics/devices/technologies that would be applicable to the Asian market. Minority or majority equity investments are made in selected companies.
As for earlier-stage companies, the firm is opportunistic in terms of sector and is open to therapeutics, medical devices and healthcare IT companies, but prefers to invest in companies with products on the market. Companies with a platform technology capable of generating several assets or a broad portfolio targeting different indications are more likely to be considered. Software-based or other Health IT oriented companies should have considerable traction, proving that their business model is viable. One of the firm’s past investments includes a biologic’s CMO.
The firm invest in companies based in the U.S. or China, and requires companies that have a proven business model, as they provide expansion capital and access to an extensive network of advisors, industry executives and business relationships to provide portfolio companies support from financial and strategic angels. Board representation is typically required along with an investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A healthcare focused venture capital firm based in New York City was formed by accomplished retinal surgeons and a team of investment professionals that have partnered to address the need for funding early stage ophthalmic focused companies. The firm is currently raising its first fund, and is currently allocating up to $750,000 utilizing convertible notes in seed stage companies and equity in post seed stage companies. The firm is interested in co-investing as part of a syndicate. The firm is currently seeking new opportunities based in North America and Europe.
The firm specializes in early-stage investments in innovative ophthalmic diagnostic and treatment solutions. The firm seeks to invest in a broad range of technologies applicable to ophthalmology, including small molecule and biologic therapeutics, low- and high-risk medical devices, diagnostics, drug delivery, and software solutions. The firm would also consider generic drugs but with less interest. The firm considers companies at all stages, but prefers early stage projects with some clinical or other supporting data where it can add meaningful expertise outside of financial capital.
The firm seeks management teams formed by experienced entrepreneurs with track records of success and scientists with domain expertise in their field. The firm opportunistically seeks board seats on a deal-by-deal basis particularly in situations where they can add meaningful value.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A strategic investment company formed by a pharma firm makes investments ranging from $3 million to $20 million acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and has filed (or will file) a US IND.
The firm invests in therapeutics, and in this sector the firm is interested in both early stage, preclinical assets and companies with assets in the clinic. The firm will consider any type of therapeutic technology (including small molecules, large molecules and gene therapies), and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases, CNS diseases and primary care indications (such as influenza) will not be considered. Drug-device combinations will also be considered.
The firm prefers to work with companies who have opened dialogue with the FDA. The firm considers a high-quality management team to be a significant requirement of their investment criteria. It is preferred that assets can reach the marketplace 3-5 years post-investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Next Phase Newsletter 